Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
160 results
  • Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism. [Journal Article]
    Chem Res Toxicol 2019Chen B, Zhang XD, … Hu GX
  • As a new atypical antipsychotic, brexpiprazole is primarily metabolized by cytochrome P450 3A4 (CYP3A4). However, genetic polymorphisms in CYP3A4 cause wide variability in individuals' responses to brexpiprazole, leading to unpredictable adverse side effects or even therapeutic failure. The present study was designed to systematically study the effects of 26 recombinant CYP3A4 variants on the met…
  • Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder. [Review]
    Drugs 2019; 79(15):1657-1677Azorin JM, Simon N
  • Bipolar disorder is a chronic, disabling, and costly illness with frequent relapses and recurrences, high rates of co-morbid conditions, and poor adherence to treatment. Mood stabilizers and antipsychotics are the cornerstones of treatment. Dopamine receptor partial agonists are a novel class of antipsychotic agents with original pharmacodynamic properties. Among them, two have been approved by t…
  • Brexpiprazole for treatment-resistant major depressive disorder. [Journal Article]
    Expert Opin Pharmacother 2019; 20(16):1925-1933Fornaro M, Fusco A, … De Berardis D
  • Introduction:Treatment-resistant depression (TRD), seldom interchangeably referred to as 'depression inadequately responding to the standard antidepressant drug,' carries a significant burden. The atypical antipsychotics represent a popular augmentation strategy for antidepressant-resistant depression, although their efficacy/safety profiles vary across different agents and presentations of depre…
New Search Next